Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib vs Docetaxel in Advanced Non-squamous NSCLC
NCT03703596Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Oct 2018
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Sichuan Cancer Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03703596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703596.